Mississippi Medicaid GLP-1 Coverage 2026: Positive-Coverage Non-Expansion Southern State — Wegovy + Saxenda Preferred Ages 12+ + SPA 23-0013 Carve-Back-In + Gainwell Single PBA

TL;DR

Mississippi Medicaid (administered by the Division of Medicaid (DOM) through the Universal Preferred Drug List, the Gainwell Technologies single statewide Pharmacy Benefit Administrator, and the MississippiCAN CCOs Magnolia / Molina / TrueCare) DOES cover GLP-1 receptor agonists for adult AND pediatric (ages 12+) chronic weight management — making Mississippi the only non-expansion southern state in the 34-state taxonomy with affirmative chronic weight-management Medicaid GLP-1 coverage.

The covered agents and PA pathways:

• Wegovy (semaglutide injection) and Saxenda (liraglutide injection) — Preferred on the Universal PDL Antiobesity Select Agents class, ages 12 and older, with manual PA required for all agents.
• Xenical (orlistat brand) and generic orlistat — Non-Preferred on the same PDL class, ages 12 and older, manual PA.
• Wegovy (semaglutide) for noncirrhotic MASH with F2–F3 fibrosis — covered separately via the Wegovy in MASH PA Criteria Version 1 (effective October 30, 2025), adult-only, gastroenterologist/hepatologist required, dose ≤ 2.4 mg weekly.

The categorical non-coverage decisions (verbatim from DOM):

• Zepbound (tirzepatide) — NOT enumerated on the Universal PDL Antiobesity Select Agents class or the Incretin Mimetics class; no published Zepbound PA Criteria document; presumptively non-covered under Miss. Admin. Code Title 23 Part 214 Rule 1.3.B.1.
• Contrave (naltrexone/bupropion) and Qsymia (phentermine/topiramate) — the DOM PA Criteria states verbatim: “This agent is not rebated through CMS.”
• Phentermine (single-agent) and Evekeo / amphetamine class — the DOM PA Criteria states: “These agents have not been shown to produce longer-term health benefits in patients who are obese or overweight.”
• Coverage during pregnancy or breastfeeding is categorically excluded.
• Concurrent use of two or more obesity agents is excluded — only one covered product at a time.

Coverage anchor architecture (5 levels):

1. 42 U.S.C. § 1396r-8(d)(2)(A) — federal optional-exclusion authority for “Agents when used for anorexia, weight loss, or weight gain.”
2. Miss. Admin. Code Title 23 Part 214 Rule 1.3.B.1 — state regulatory reproduction of the federal exclusion: “Drugs when used for anorexia, weight loss, or weight gain.”
3. Mississippi State Plan Amendment SPA 23-0013 (effective July 1, 2023) — the federally-approved carve-back-in that authorizes DOM-specified obesity-treatment coverage notwithstanding Rule 1.3.B.1.
4. DOM Anti-obesity Select Agents PA Criteria Version 10 (effective April 1, 2026) — the operational coverage scope: Wegovy + Saxenda Preferred ages 12+; Xenical + orlistat Non-Preferred ages 12+; Contrave / Qsymia / phentermine / Evekeo categorically non-covered.
5. Universal Preferred Drug List Version 2026_1 (effective January 1, 2026, updated November 4, 2025) — the formulary-status anchor for all covered agents.

Mississippi predates Tennessee by approximately two years as the earliest-adopting non-expansion southern state for chronic-weight-management Medicaid GLP-1 coverage. Coverage began in 2023 per KFF Health News reporting. Operational uptake has been low — just 2% of adults meeting weight-related criteria had been prescribed a GLP-1 as of December 2024, with approximately 2,900 enrollees age 12 or older starting treatment in the first 15 months at a total DOM spend of approximately $12 million.

1. Federal authority: 42 U.S.C. § 1396r-8(d)(2)(A)

The federal Medicaid drug rebate statute at 42 U.S.C. § 1396r-8(d)(2) grants states an optional authority to exclude certain drug classes from Medicaid coverage. The relevant verbatim text:

“Subject to subsection (d)(3), the following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted:

(A) Agents when used for anorexia, weight loss, or weight gain. …”

This authority is permissive, not mandatory. States that exercise the exclusion bar coverage of obesity drugs entirely; states that do not exercise the exclusion (or that subsequently partially reverse via State Plan Amendment) may cover obesity drugs subject to their own PA criteria.

Mississippi initially exercised the (A) exclusion via Miss. Admin. Code Title 23 Part 214 Rule 1.3.B.1 (next section) and subsequently partially reversed via SPA 23-0013 (effective July 1, 2023) to carve back in DOM-specified obesity-treatment agents. This dual-step posture is structurally distinctive in the southern non-expansion cluster — Texas (Pattern #1), Florida (Pattern #4), Georgia (Pattern #8), Alabama (Pattern #23), Oklahoma (Pattern #24), South Carolina (Pattern #31), Louisiana (Pattern #28), and Arkansas (Pattern #34) have not executed an analogous carve-back-in for chronic weight management.

2. State regulatory anchor: Miss. Admin. Code Title 23 Part 214 Rule 1.3.B.1

DOM's state regulatory reproduction of the federal optional exclusion appears in Miss. Admin. Code Title 23 (Division of Medicaid) Part 214 (Pharmacy Services) Chapter 1 Rule 1.3 (Drugs Subject to Exclusion or Otherwise Restricted). Relevant verbatim text:

“Rule 1.3: Drugs Subject to Exclusion or Otherwise Restricted

B. Medicaid excluded or otherwise restricted drugs include, but are not limited to:

1. Drugs when used for anorexia, weight loss, or weight gain,

… 17. Drugs produced by manufacturers that do not have signed rebate agreements with the federal government as required by the Omnibus Budget Reconciliation Act (OBRA) of 1990, unless provided through expanded EPSDT services in Miss. Admin. Code Part 223 …”

Rule 1.3.B.1 reproduces the federal “Agents when used for anorexia, weight loss, or weight gain” exclusion at the state regulatory level — making the categorical exclusion the regulatory baseline. Rule 1.3.B.17 reinforces the federal CMS rebate-agreement requirement, which is later cited as the rationale for non-coverage of Contrave and Qsymia.

The carve-back-in mechanism for Wegovy, Saxenda, and orlistat does not appear in Rule 1.3 itself — it is operationalized at the State Plan Amendment level (SPA 23-0013) and expressed at the PDL + PA Criteria document level. The article's framing should therefore treat Rule 1.3.B.1 as the regulatory baseline and SPA 23-0013 + the PDL Antiobesity Select Agents class + the PA Criteria document as the operative coverage scope.

3. SPA 23-0013: the carve-back-in (effective July 1, 2023)

Mississippi State Plan Amendment SPA 23-0013 (effective July 1, 2023; operationalized through a DOM administrative-code filing finalized October 23, 2023, effective December 1, 2023) is the federally-approved instrument that authorizes DOM to cover obesity-treatment agents notwithstanding Rule 1.3.B.1's categorical exclusion.

SPA 23-0013 is the legal mechanism — the carve-back-in does not happen via legislative mandate. DOM's authority to file and operate under SPA 23-0013 derives from Miss. Code Ann. § 43-13-121 (general DOM authority) and § 43-13-117(A)(9) (prescription drug authority). The carve-back-in scope is determined operationally by DOM through the PA Criteria document and the Universal PDL — both subject to ongoing modification under Miss. Admin. Code Title 23 Part 214 Rule 1.10.E (“The PDL is subject to change”).

Coverage timeline confirmation via KFF Health News reporting October 15, 2025: “Mississippi Medicaid in 2023 began covering GLP-1s for people 12 and older.” DOM spokesperson Matt Westerfield articulated the program rationale verbatim: DOM approved these drugs “on the logic that treating obesity would improve enrollees' health and eventually could lead to cost savings.”

The 2023 coverage adoption preceded Tennessee's TennCare AOM expansion (Pattern #13, Public Chapter 530 of 2025) by approximately two years, making Mississippi the earliest-adopting non-expansion southern state in the 34-state series for chronic-weight-management Medicaid GLP-1 coverage.

4. What MS Medicaid covers vs. does not cover

The Universal Preferred Drug List Version 2026_1 (effective January 1, 2026, updated November 4, 2025) and the Anti-obesity Select Agents PA Criteria Version 10 (effective April 1, 2026) together define the operational coverage scope:

5. Adult initial PA criteria (Wegovy or Saxenda)

Per the DOM Anti-obesity Select Agents PA Criteria Version 10 (effective April 1, 2026):

“I. Initial Authorization: 12 Months

A. Adults (18 year or older) – Saxenda or Wegovy

BMI 30 or greater

BMI 25 to 29 for Wegovy OR BMI 27 to 29 for Saxenda with at least one weight-related comorbidity:

Hypertension – Confirmed by claims history of antihypertensive medication.

Hyperlipidemia – Confirmed by claims history of antihyperlipidemic medication, OR lipid panel (Total Chol., LDL, HDL, TG).

Glucose dysregulation – Diabetes with history of glucose lowering medication, OR pre-diabetes (fasting glucose > 100, 2-hour OGTT > 140, or HbA1C > 5.7%).

Obstructive sleep apnea – Confirmed by prior sleep study.

Cardiovascular disease – coronary artery disease, heart failure, prior MI or CVA

Metabolic dysfunction-associated steatotic liver disease [MASLD; formerly known as non-alcoholic fatty liver disease (NAFLD)]

Other (attach detailed clinical justification)”

Two operational notes that prescribers and members frequently miss:

• The BMI threshold differs by drug. Wegovy accepts BMI 25–29 with comorbidity; Saxenda accepts BMI 27–29 with comorbidity. This reflects FDA-label differences at the lower BMI tier.
• Claims-history confirmation suffices for hypertension, hyperlipidemia, and diabetes — no separate prescriber note required if pharmacy claims show antihypertensive, antihyperlipidemic, or glucose-lowering medication use. For pre-diabetes and other comorbidities, a lab value or sleep-study report is required.

Initial PA is approved for 12 months. Reauthorization criteria appear in Section 7 below.

Treatment plan requirement. Per the verbatim DOM PA form, all initial Wegovy/Saxenda PAs require an attached 12-month treatment plan with: current BMI, current weight, current height (with dates), 12-month treatment goal BMI/weight, non-scale treatment goals, treatment plan expected duration, and an attestation that the patient has been counseled on appropriate dietary choices and increasing physical activity. The treatment plan attachment is a structurally distinctive operational requirement — many other states do not require a formal treatment plan at initial PA.

6. Pediatric initial PA criteria (ages 12–17)

Mississippi is the only state in the 34-state series with operationalized pediatric chronic-weight-management Medicaid GLP-1 coverage. Per the DOM PA Criteria Version 10:

“B. Children (age 12 - 17 years) – Saxenda or Wegovy

Saxenda:

Body weight above 60 kg, AND Initial BMI corresponding to 30 or greater for adults by international cut-offs

Wegovy:

BMI at > 95th percentile for age and sex”

The DOM PA form reproduces the CDC growth-chart BMI-at-95th-percentile table for prescriber convenience:

Notable: the Saxenda pediatric pathway requires body weight > 60 kg in addition to the BMI-30-equivalent threshold, reflecting Novo Nordisk's pediatric labeling for liraglutide. Wegovy uses the BMI-percentile standard alone.

Reauthorization criteria for pediatric patients: the renewal threshold is “achieved or maintained a reduction from baseline BMI” — not the adult ≥ 5% weight loss threshold. This recognizes growth-related body composition changes during adolescence.

7. Reauthorization criteria (12 months)

Per DOM PA Criteria Version 10 Section II:

“Reauthorization to continue treatment is subject to the following:

Yes/No: Has patient been adherent, as evidenced in paid pharmacy claims? Adherence is defined as at least 9 claims in the past year.

Yes/No: Is the member tolerating the recommended maintenance or target dosage of the requested agent as outlined in the agent's package insert? If the patient is not on the maintenance or target dose, please provide an explanation below.

Yes/No: Does the patient meet one of the following scenarios?

Yes/No: If the member is a pediatric patient, has the member achieved or maintained a reduction from baseline BMI?

Yes/No: Has the member achieved or maintained a weight loss of 5% or greater from baseline weight?”

Three operational triggers for reauthorization approval:

• Adherence ≥ 9 paid pharmacy claims in the past year. Operationally this allows for roughly 10–11 monthly fills with 1–2 gaps tolerated — consistent with FDA-label maintenance dosing and patient real-world tolerance pauses.
• Tolerance of the maintenance / target dose per the package insert (Wegovy 2.4 mg weekly maintenance, Saxenda 3.0 mg daily maintenance). If the patient is on a sub-maintenance dose, the prescriber must provide a clinical-justification explanation (typically gastrointestinal intolerance).
• Clinical effectiveness: adult patients must have achieved or maintained ≥ 5% weight loss from baseline weight; pediatric patients must have achieved or maintained a reduction from baseline BMI.

Notable absences in Mississippi's reauthorization framework:

• No BMI-floor renewal revocation. Wisconsin (Pattern #19) revokes Medicaid GLP-1 coverage if BMI falls below 24. Mississippi has no analog — a patient who reaches a BMI of 22 still qualifies for reauthorization if they meet the ≥ 5% baseline-weight-loss threshold and adherence/tolerance tests.
• No lifetime-attempts cap. New York (Pattern #3) limits members to 2 lifetime obesity-drug trial attempts. Mississippi has no analog — a member can re-initiate Wegovy/Saxenda treatment indefinitely if they meet the initial PA criteria each cycle.
• No mandatory weight-loss-program enrollment. Some states require concurrent enrollment in a clinical weight-loss program. Mississippi requires only an attestation of dietary/physical-activity counseling at PA submission and renewal — not third-party program enrollment.

8. The Wegovy in MASH PA Criteria Version 1 (effective Oct 30, 2025)

Wegovy received an FDA label expansion in August 2025 for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with moderate-to-advanced fibrosis (F2–F3). Mississippi DOM operationalized that label expansion through a separate standalone PA Criteria document — not by extending the Antiobesity Select Agents class.

“WEGOVY® (semaglutide) PA Criteria FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH):

WEGOVY® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) … with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults.”

Initial PA criteria (12 months):

1. Age of the patient is within the age range as recommended by the FDA label (currently adults only per Wegovy's MASH FDA label).
2. Patient has a diagnosis of noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), confirmed by clinical presentation AND laboratory findings AND/OR imaging AND/OR biopsy results.
3. Patient does NOT have decompensated cirrhosis.
4. Prescribed by or in consultation with a gastroenterologist or hepatologist.
5. Prescriber attests Wegovy will be used WITH diet and exercise and WITHOUT excessive alcohol consumption.
6. Prescribed dosage does NOT exceed Wegovy 2.4 mg subcutaneously once weekly.

Reauthorization (12 months) requires continued initial-criteria satisfaction, documentation of positive clinical response (improvement or stabilization of fibrosis), and maintenance on Wegovy 2.4 mg or 1.7 mg weekly.

Critical operational distinction: the MASH PA pathway is independent of the chronic-weight-management pathway. A patient with F2–F3 MASH but BMI < 30 + no comorbidities — who would not qualify for the obesity pathway — can still qualify for Wegovy under the MASH PA Criteria if they meet the fibrosis, specialist, and dose criteria. Likewise, a patient already approved for Wegovy under the Antiobesity Select Agents class does not need a separate MASH PA to continue therapy.

Mississippi's MASH PA Criteria is structurally similar to Arkansas's October 2025 MASH carve-out (Pattern #34), with both states adopting Wegovy MASH coverage in late 2025 following the FDA's August 2025 label expansion. Oklahoma (Pattern #24) and Iowa (Pattern #32) also adopted Wegovy MASH carve-outs in the same window.

9. Non-covered obesity drugs: the verbatim DOM rationale

The DOM PA Criteria Version 10 lists three categorical non-coverage rationales — each is structurally distinctive and the article reproduces them verbatim to preserve the regulatory framing:

“The following agents are not covered by Mississippi Medicaid:

Contrave – This agent is not rebated through CMS.

Qsymia – This agent is not rebated through CMS.

Phentermine, Evekeo/amphetamine – These agents have not been shown to produce longer-term health benefits in patients who are obese or overweight.”

Two non-coverage rationales operate here:

• CMS rebate-agreement non-participation for Contrave and Qsymia. The federal CMS Drug Rebate Program (42 U.S.C. § 1396r-8(a)) requires manufacturers to enter rebate agreements with HHS as a condition of Medicaid reimbursement for their products. Miss. Admin. Code Title 23 Part 214 Rule 1.3.B.17 reinforces this requirement at the state level. If a manufacturer does not have a signed rebate agreement, the drug is categorically non-coverable under Medicaid — not as a clinical or policy decision but as a federal-statutory consequence.
• Clinical-evidence rationale for phentermine (single-agent including Adipex-P and Lomaira) and Evekeo / amphetamine class. DOM's position is that these agents have not been shown to produce longer-term health benefits. This is a substantive coverage decision — not a rebate-status decision — and reflects DOM's alignment with the FDA's long-standing concerns about long-term efficacy and cardiovascular safety of stimulant-class anti-obesity drugs.

Mississippi is the only state in the 34-state series with the explicit CMS-rebate-agreement-non-participation citation as the non-coverage rationale for Contrave and Qsymia. Other states cite “no clinical evidence,” “not on formulary,” or “high cost” as the non-coverage rationale for the same drugs. The MS framing is structurally cleaner because it anchors the non-coverage decision to a federal-statutory fact (manufacturer rebate participation) rather than a discretionary clinical-policy judgment.

10. Categorical exclusions: pregnancy, breastfeeding, concurrent use, contraindications

The DOM PA Criteria Version 10 includes four additional categorical exclusion clauses that prescribers and members frequently overlook. All quotes are verbatim:

10.1 Pregnancy and breastfeeding

“Mississippi Medicaid does not cover medications for treatment of obesity during pregnancy or for mothers who are breast-feeding.”

DOM categorically excludes obesity-drug coverage during pregnancy AND during the breastfeeding period. This reflects FDA-label warnings on Wegovy and Saxenda regarding pregnancy and is consistent with the standard pharmacotherapy pause practice during lactation.

10.2 Concurrent-use exclusion

“Coverage of select medications for the treatment of obesity will be limited to only one covered product at a given time. Mississippi Medicaid will not cover concurrent use of two or more agents for the treatment of obesity.”

A member on Wegovy cannot simultaneously be approved for Saxenda or orlistat. The renewal PA explicitly verifies non-concurrent use. This is a one-at-a-time rule and is structurally important for understanding the operational scope.

10.3 Contraindication warnings

“Note: Saxenda and Wegovy are GLP-1 agonists and should be avoided in patients with multiple endocrine neoplasia syndrome type 2 or a personal/family history of medullary thyroid carcinoma. They are contraindicated for concomitant use with other GLP-1 agonists or DPP-4 inhibitors.”

DOM reproduces the standard FDA-label contraindications: MEN2 or MTC personal/family history, and contraindicated concurrent use with other GLP-1 agonists or DPP-4 inhibitors. The latter reinforces the one-at-a-time rule across drug classes.

10.4 Medicare Part D dual-eligible cost-avoidance

“Medicaid is the payer of last resort. In accordance with Medicaid's cost avoidance requirements, for members who have Medicare Part D as their primary coverage, all efforts through Medicare Part D should be exhausted up to and including an Appeal. Please submit a copy of the Appeal denial letter along with supporting clinical documentation and required PA forms for review for coverage by MS Medicaid. Please note: Medicaid does not cover Medicare Part D copay.”

For Medicare-Medicaid dual eligibles (a structurally large MS Medicaid sub-population given disability and elderly dual coverage rates), the Medicare Part D appeal must be exhausted first — including an internal appeal at the Part D plan — before DOM will review a PA for chronic-weight-management Wegovy or Saxenda. DOM does not cover the Part D copay, which can be a barrier for low-income beneficiaries.

11. Universal PDL Version 2026_1: Antiobesity vs. Incretin Mimetics

The Mississippi Universal Preferred Drug List (Version 2026_1, effective January 1, 2026, updated November 4, 2025) lists GLP-1 and obesity drugs in two structurally distinct classes:

11.1 ANTIOBESITY SELECT AGENTS class (verbatim)

“ANTIOBESITY SELECT AGENTS

PREFERRED AGENTS: SAXENDA (liraglutide), WEGOVY (semaglutide)

NON-PREFERRED AGENTS: liraglutide, orlistat, XENICAL (orlistat)

PA CRITERIA: All agents MANUAL PA required”

Key features:

• Manual PA required for all agents — even Preferred Saxenda and Wegovy require a manual PA submission. There is no auto-approval, point-of-sale-only, or electronic-PA-only pathway.
• Generic liraglutide appears Non-Preferred in this class. Generic liraglutide can be billed under either the Antiobesity Select Agents class (for chronic weight management, with the PA Criteria document's obesity-treatment criteria governing) or the Hypoglycemics-Incretin Mimetics class (for T2D treatment, with the T2D criteria governing).

11.2 HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS class

The T2D-indicated GLP-1 receptor agonists appear in a separate PDL class with their own PA pathway:

• Preferred (T2D): Byetta (exenatide), Trulicity (dulaglutide), Victoza (liraglutide)
• Non-Preferred (T2D): Mounjaro (tirzepatide), Ozempic (semaglutide), Rybelsus (oral semaglutide), Bydureon (exenatide ER), Soliqua (insulin glargine/lixisenatide), Symlinpen (pramlintide), Xultophy (insulin degludec/liraglutide)

The recurring T2D-pathway criterion across the Non-Preferred agents is: “Documented diagnosis of Type 2 Diabetes AND No history of SAXENDA or WEGOVY in the past 30 days.”

This “no history of Saxenda or Wegovy in past 30 days” clause is structurally significant — it prevents formulary cross-utilization between the obesity pathway (Antiobesity Select Agents) and the T2D pathway (Incretin Mimetics), and operationally reinforces the categorical separation of indications. A member cannot bounce from Wegovy to Ozempic by re-indicating off-label for “T2D” without a 30-day washout.

Off-label prescribing not reimbursed. The T2D-indicated agents are covered only when the patient has an FDA-approved diagnosis of type-2 diabetes mellitus. Members seeking chronic-weight-management GLP-1 therapy must be routed to Wegovy or Saxenda — not to off-label use of Ozempic, Mounjaro, or Rybelsus.

12. Gainwell Technologies SPBA + MississippiCAN CCOs

Mississippi has a structurally simple pharmacy benefit architecture — the simplest in the 34-state series:

12.1 Single Pharmacy Benefit Administrator

Gainwell Technologies is the single statewide Pharmacy Benefit Administrator (SPBA), effective July 1, 2024. Per the DOM Pharmacy page, verbatim:

“On July 1, the Mississippi Division of Medicaid (DOM) will implement a single Pharmacy Benefit Administrator (PBA) to streamline and enhance the processing and management of pharmacy claims for all Medicaid members, including those enrolled in MississippiCAN and CHIP.”

Gainwell's scope of work covers:

• Processing pharmacy claims for FFS + MSCAN + MSCHIP
• All pharmacy prior authorization adjudication
• Pharmacy call center / help desk: 1-833-660-2402 (toll-free)
• PA fax: 1-866-644-6147
• Point-of-sale billing: BIN 025151, PCN DRMSPROD (effective 7/1/2024)
• Mailing address: Gainwell Technologies, PO Box 2480, Ridgeland, MS 39158
• MESA Provider Portal: ms-medicaid-mesa.com — preferred for fastest processing

Prior to July 1, 2024, Mississippi Medicaid used Conduent as the FFS fiscal agent + a split CCO-administered pharmacy architecture (each CCO had its own PBM and formulary). The transition to the Gainwell point-of-sale system went live at 6:00 a.m. CST on Saturday, October 1, 2022 for FFS, and the SPBA-unified architecture extended Gainwell's role to all Medicaid populations effective July 1, 2024.

12.2 MississippiCAN CCOs (Aug 12, 2024 – Aug 11, 2028)

Three CCOs administer medical-benefit care under the current four-year contract cycle:

• Magnolia Health Plan, Inc. (Centene subsidiary)
• Molina Healthcare of Mississippi, Inc.
• Mississippi True d/b/a TrueCare — the new CCO that replaced UnitedHealthcare in the June 2024 procurement

UnitedHealthcare is NOT a current MississippiCAN CCO. Members previously enrolled with UHC were transitioned to one of the three current CCOs during the August 2024 contract cycle. CHIP managed care was unified under the same three CCOs effective July 1, 2025.

Pharmacy benefits are carved out from CCO medical-benefit administration and consolidated under Gainwell. This means:

• The same Universal PDL applies to all Mississippi Medicaid beneficiaries — whether they are enrolled in FFS, Magnolia, Molina, or TrueCare.
• Pharmacy PAs go to Gainwell at 1-833-660-2402 or fax 1-866-644-6147 — not to the specific CCO.
• Medical-benefit questions (physician visits, hospital care, MASLD/MASH workup, sleep studies, weight-loss counseling) DO depend on CCO assignment — those services are administered by the assigned CCO.

This is structurally simpler than:

• Arkansas's three-program bifurcation (Pattern #34, FFS + PASSE + ARHOME QHPs operating outside the state PDL)
• Kentucky's five-MCO MedImpact deferral architecture (Pattern #21)
• Indiana's MCO + OptumRx SUPDL split (Pattern #16)
• Texas's MCO formulary + Acentra FFS PBM split (Pattern #1)
• New York's NYRx FFS-only-carve-out architecture (Pattern #3)

13. Operational uptake: KFF Health News reporting

Per KFF Health News, “In Mississippi, Medicaid Coverage of Weight Loss Drugs Fails To Catch On” (October 15, 2025):

“Mississippi Medicaid in 2023 began covering GLP-1s for people 12 and older.”

“Just 2% of adults on Mississippi Medicaid who meet the weight-related criteria had been prescribed a GLP-1 as of December 2024.”

“only about 2,900 Medicaid enrollees age 12 or older started treatment” in the first 15 months.

The state spent “$12 million in the first 15 months, providing the weight loss drugs to 2,200 adult members.”

“Most enrollees using the drugs lived in the southern, central, or northern parts of Mississippi — not along the Mississippi Delta on the western side of the state, where obesity rates are highest, at nearly 50%.”

Five operational findings emerge from the KFF reporting:

1. Coverage policy began in 2023, making MS the earliest-adopting non-expansion southern state in the 34-state series — approximately two years before Tennessee's TennCare AOM expansion (Pattern #13).
2. Uptake is operationally low — 2% of adults meeting weight criteria received a GLP-1 by December 2024. The gap between policy availability and operational uptake is structurally important.
3. ~2,900 enrollees (including 2,200 adults) received GLP-1s in the first 15 months. The pediatric population is small (~700 enrollees ages 12–17) but operationally non-zero.
4. DOM spending in the first 15 months: $12 million. At approximately $1,300/month for Wegovy WAC and $1,349/month for Saxenda WAC, the operational spend per adult member averaged approximately $5,400/year — below the per-member WAC because of CMS rebate offsets.
5. Geographic disparity: the Mississippi Delta (highest obesity prevalence at ~50%) has LOWER GLP-1 uptake than other regions — suggesting access barriers (provider availability, awareness, transportation) beyond formulary coverage. This is a coverage-policy success that has not yet translated to operational equity.

DOM's policy rationale, verbatim from spokesperson Matt Westerfield: DOM approved these drugs “on the logic that treating obesity would improve enrollees' health and eventually could lead to cost savings.”

For prescribers and members reading this article: the gap between policy availability and operational uptake is a practical opportunity. ELIGIBLE Mississippians who meet the PA criteria have a real coverage pathway available — and the low uptake numbers reflect access friction rather than program restriction. Patients in the Mississippi Delta region in particular may benefit from active prescriber outreach, telehealth-mediated PA initiation, and transportation support to initiate therapy.

14. Appeals pathway

The Mississippi Medicaid appeals authority is 23 Miss. Admin. Code Part 300, Chapter 3, Rule 3.1. DOM operates a SharePoint-based portal for filing appeals. Per the DOM Appeals page, verbatim:

“The Mississippi Division of Medicaid has created a SharePoint based portal for appeals brought pursuant to 23 Mississippi Administrative Code, Part 300, Chapter 3, Rule 3.1. You must be granted access to use the portal. If you would like to request access, you may email Medicaid.Appeals@medicaid.ms.gov.”

The standard federal-state Medicaid appeals framework under 42 C.F.R. § 431 Subpart E (“Fair Hearings for Applicants and Recipients”) requires DOM to provide:

• Written notice of the adverse action with appeal rights.
• A reasonable opportunity to request a fair hearing (typically 90 days from notice under federal regulation, though MS-specific deadlines under Rule 3.1 may differ — the verbatim Rule 3.1 text is not published on the DOM Appeals page, so the MS-specific deadline should be confirmed at the time of denial).
• A hearing before an impartial decision-maker.
• The right to continue benefits pending the fair hearing decision if requested within 10 days of notice (for ongoing services).
• A final administrative decision.

Practical denial-recovery path for a Wegovy or Saxenda PA denial:

1. Internal reconsideration at Gainwell: re-submit the PA with additional clinical justification — updated BMI documentation, comorbidity confirmation, attached treatment plan, prescriber LOMN engaging the specific clause cited in the denial.
2. Written appeal to DOM via the Medicaid Appeals SharePoint portal. Email Medicaid.Appeals@medicaid.ms.gov to request portal access.
3. Fair hearing before an impartial decision-maker.
4. Final administrative decision issued by the DOM Executive Director or designee.
5. Judicial review available under the Mississippi Administrative Procedures Law (Miss. Code Ann. §§ 25-43-3.115 et seq.) after the final administrative decision is issued.

The Gainwell Help Desk at 1-833-660-2402 is the first practical contact for PA disputes — many denials can be resolved through clarification or re-submission without entering the formal appeals track. Prescribers should call Gainwell first to identify whether the denial was for a documentation deficiency (recoverable via re-submission) or a categorical criterion failure (which requires either qualifying criteria documentation or formal appeal).

Appeal posture for chronic-weight-management denials: because MS DOES cover chronic-weight-management GLP-1s for qualifying members, denials in this category are typically documentation-deficiency denials, not categorical denials. The strongest appeals posture is to document the qualifying BMI + comorbidity profile + treatment plan and re-submit. For Zepbound requests specifically, the appeal posture is weaker — Zepbound is presumptively non-covered under Rule 1.3.B.1, so an appeal requesting Zepbound coverage cannot be granted absent DOM policy change.

15. Mississippi vs. the 34-state taxonomy

The taxonomy positioning of Mississippi (Pattern #35) within the broader 50-state series:

15.1 Vs. non-expansion southern peers

• Texas (Pattern #1) — categorical exclusion + PDL absence. MS goes affirmatively the opposite direction.
• Florida (Pattern #4) — silent operational exclusion via PDL absence. MS is the inverse: explicit carve-back-in for Wegovy + Saxenda.
• Georgia (Pattern #8) — dual-level operational non-coverage with statewide PDL omission. MS's Universal PDL explicitly includes Wegovy + Saxenda Preferred.
• Alabama (Pattern #23) — PDL-enumerated OSA-only Zepbound carve-out + off-PDL Wegovy MACE PA Form 369. Coverage is FDA-label-indication-restricted to OSA and MACE only. MS's coverage is the inverse: explicit chronic-weight-management coverage with NO published OSA or MACE carve-outs and NO Zepbound coverage at all.
• Oklahoma (Pattern #24) — triple-carve-out regulatory exclusion (Wegovy CV + MASH + Zepbound OSA + Imcivree monogenic). OK has more FDA-label-restricted carve-outs than MS but lacks MS's chronic-weight-management coverage.
• Arkansas (Pattern #34) — three-program-bifurcated regulatory exclusion with three carve-outs (Wegovy CV + Zepbound OSA + Wegovy MASH). AR is the closest non-coverage southern peer in pharmacy benefit architecture (both use a single statewide PBM) but the opposite policy direction.
• South Carolina (Pattern #31) and Louisiana (Pattern #28) — non-coverage southern peers. MS diverges from both postures.
• Tennessee (Pattern #13) — moved affirmatively toward chronic-weight-management coverage in 2025–2026 via TennCare Sequence 10-34-25 (Public Chapter 530). MS predates TN by approximately two years — MS coverage began in 2023; TN's expansion is 2025–2026 phase-in.

15.2 Vs. positive-coverage peers (expansion states)

• Missouri (Pattern #22) — covers Wegovy + Zepbound + Foundayo on a dedicated Anti-Obesity PDL class. MS covers Wegovy + Saxenda only. MO is operationally broader at the drug-set level.
• Maryland (Pattern #17) — positive coverage with the MMPP “Anti-Obesity Drugs” class. MS uses the Universal PDL Antiobesity Select Agents class. MD's class is broader (likely including Zepbound and Foundayo).
• Massachusetts (Pattern #15) — positive coverage with MassHealth PDL “Anti-Obesity Agents” class. MA and MS share the affirmative-coverage posture, but MA is an expansion state.
• Wisconsin (Pattern #19) — affirmative coverage with a 2-lifetime-attempts cap + BMI < 24 renewal-revocation. MS has no lifetime cap and no BMI-floor renewal-revocation — making MS's reauthorization pathway operationally more sustainable for long-term obesity management.
• Minnesota (Pattern #20) — affirmative coverage with a dedicated Weight Management Agents PDL class. Structurally aligned with MS, but MN is an expansion state.
• Virginia (Pattern #18) — affirmative obesity-indication coverage with explicit DMAS PA criteria. Structurally aligned with MS, but VA is an expansion state.
• North Carolina (Pattern #9) — double-reversed in 2025 (terminated October 2025, reinstated December 2025). MS has stable coverage since 2023 with no policy reversal.

15.3 Distinctive features

Mississippi is the only state in the 34-state series with:

• Affirmative chronic-weight-management coverage as a non-expansion southern state.
• Operationalized pediatric (ages 12–17) chronic-weight-management coverage with CDC growth-chart BMI-percentile criteria embedded in the PA form.
• Universal PDL covering FFS + managed care + CHIP uniformly through a single Pharmacy Benefit Administrator (Gainwell), with no CCO-specific formulary deviation.
• Explicit DOM PA Criteria language “This agent is not rebated through CMS” as the non-coverage rationale for Contrave and Qsymia — tracing back to Miss. Admin. Code Title 23 Part 214 Rule 1.3.B.17 and the federal CMS rebate agreement requirement.
• SPBA architecture documented at primary-source level (April 2024 Provider Bulletin) with the July 1, 2024 Gainwell implementation replacing the prior Conduent-administered FFS + CCO-split architecture.

Frequently asked questions